

A Phase 2A Trial of MM402 for Autism Spectrum Disorder

NCT07303907

Status	RECRUITING
Phase	Phase 2
Sponsor	Definium Therapeutics US, Inc.
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (3)

- Diagnosis of ASD per records as confirmed by standard semi-structured interview for Autism diagnosis (eg, Autism Diagnostic Observation Schedule-Second Edition)
- Male or Female aged 18 to 45
- Presents with clinically significant deficits in socialization and communication as determined by Social Responsiveness Scales (SRS-2) e66

Exclusion (4)

- Has uncorrected abnormalities in eye movement, alignment, or acuity or atypical eye features that could interfere with eye tracking
- First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
- Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
- Any clinically significant unstable illness

Locations (1 total)

Spectrum Neuroscience and Treatment Institute, New York, New York, United States